ES2531599T3 - Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales - Google Patents

Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales Download PDF

Info

Publication number
ES2531599T3
ES2531599T3 ES06754856.0T ES06754856T ES2531599T3 ES 2531599 T3 ES2531599 T3 ES 2531599T3 ES 06754856 T ES06754856 T ES 06754856T ES 2531599 T3 ES2531599 T3 ES 2531599T3
Authority
ES
Spain
Prior art keywords
treatment
docosahexaenoic
triglycerides
tumor diseases
docosahexaenoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06754856.0T
Other languages
English (en)
Inventor
J.C. Domingo Pedrol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brudy Technology SL
Original Assignee
Brudy Technology SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brudy Technology SL filed Critical Brudy Technology SL
Application granted granted Critical
Publication of ES2531599T3 publication Critical patent/ES2531599T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilización de un aceite enriquecido en ácido docosahexaenoico (DHA) para la fabricación de una composición farmacéutica destinada al tratamiento de una enfermedad tumoral, estando dicho ácido docosahexaenoico en un porcentaje de al menos el 50% en peso con respecto al total de ácidos grasos en dicho aceite; en la que dicho "aceite enriquecido en ácido docosahexaenoico" significa derivados de glicerol naturales o sintéticos que contienen 50-100% en peso del grupo docosahexaenoílo en base al contenido total de ácidos grasos, estando dichos derivados de glicerol en forma de triglicérido.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES06754856.0T 2005-05-12 2006-04-26 Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales Active ES2531599T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200501141 2005-05-12
ES200501141A ES2264886B1 (es) 2005-05-12 2005-05-12 Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
PCT/EP2006/061833 WO2006120120A1 (en) 2005-05-12 2006-04-26 Use of docosahexaenoic glycerides for the treatment of tumorous diseases

Publications (1)

Publication Number Publication Date
ES2531599T3 true ES2531599T3 (es) 2015-03-17

Family

ID=36809521

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200501141A Active ES2264886B1 (es) 2005-05-12 2005-05-12 Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
ES06754856.0T Active ES2531599T3 (es) 2005-05-12 2006-04-26 Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES200501141A Active ES2264886B1 (es) 2005-05-12 2005-05-12 Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Country Status (13)

Country Link
US (3) US20080207947A1 (es)
EP (1) EP1881824B1 (es)
JP (2) JP5893235B2 (es)
CA (1) CA2614192C (es)
DK (1) DK1881824T3 (es)
ES (2) ES2264886B1 (es)
HK (1) HK1113319A1 (es)
IL (1) IL187274A (es)
NO (1) NO336953B1 (es)
NZ (1) NZ563301A (es)
PL (1) PL1881824T3 (es)
PT (1) PT1881824E (es)
WO (1) WO2006120120A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
RU2437583C2 (ru) * 2005-12-21 2011-12-27 Бруди Текнолоджи, С.Л. Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
NZ586249A (en) * 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
WO2011103514A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha triglyceride emulsions
WO2011103512A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha free fatty acid emulsions
JP5847475B2 (ja) * 2010-07-26 2016-01-20 富士フイルム株式会社 油脂含有組成物、及びそれを含む経口製剤
ES2753387T3 (es) 2013-04-22 2020-04-08 Smartfish As Uso de una composición que comprende aceite de pescado y zumo para el tratamiento y/o tratamiento posterior del cáncer
KR101665253B1 (ko) 2015-06-19 2016-10-25 순천향대학교 산학협력단 도코사헥사에노산 및 트리아신 씨를 포함하는 것을 특징으로 하는 자궁내막암 치료 및 예방용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3721137A1 (de) * 1987-06-26 1989-01-05 Dietl Hans Fettemulsion zur intravenoesen anwendung
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JP2572692B2 (ja) * 1991-07-24 1997-01-16 ボーソー油脂 株式会社 ドコサヘキサエン酸トリグリセリドの製造法
JPH05139968A (ja) * 1991-11-14 1993-06-08 Sagami Chem Res Center メダラシン活性促進剤
JPH0616548A (ja) * 1992-06-30 1994-01-25 Sagami Chem Res Center 組織異常増殖抑制剤
JPH06116585A (ja) * 1992-10-09 1994-04-26 Kanegafuchi Chem Ind Co Ltd 油脂の精製方法
JP3526632B2 (ja) * 1994-08-22 2004-05-17 旭化成ケミカルズ株式会社 高度不飽和脂肪酸含有油脂
JPH1057086A (ja) * 1996-08-20 1998-03-03 Asahi Chem Ind Co Ltd 高濃度ドコサヘキサエン酸モノグリセリドの製造方法
WO2001017524A1 (en) * 1999-09-09 2001-03-15 Efa Sciences Llc. Methods for treating cell proliferative disorders including cancer
JP2002180082A (ja) * 2000-12-11 2002-06-26 Maruha Corp 摂取物
US20040052837A1 (en) * 2002-06-27 2004-03-18 William Stillwell Lipid conjugated anti-cancer drugs and methods of use thereof
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
PL1881824T3 (pl) 2015-06-30
IL187274A0 (en) 2008-06-05
EP1881824A1 (en) 2008-01-30
JP6038841B2 (ja) 2016-12-07
CA2614192C (en) 2014-03-18
NO336953B1 (no) 2015-11-30
ES2264886A1 (es) 2007-01-16
US9271954B2 (en) 2016-03-01
CA2614192A1 (en) 2006-11-16
US20090318553A1 (en) 2009-12-24
DK1881824T3 (en) 2015-02-23
JP5893235B2 (ja) 2016-03-23
US20160193175A1 (en) 2016-07-07
JP2008540484A (ja) 2008-11-20
US20080207947A1 (en) 2008-08-28
HK1113319A1 (en) 2008-10-03
EP1881824B1 (en) 2014-12-24
PT1881824E (pt) 2015-03-26
JP2014208677A (ja) 2014-11-06
US20170333381A9 (en) 2017-11-23
WO2006120120A1 (en) 2006-11-16
NO20076382L (no) 2008-02-08
ES2264886B1 (es) 2008-02-01
IL187274A (en) 2011-11-30
NZ563301A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
ES2531599T3 (es) Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales
NI202100009A (es) Métodos para reducir la necesidad de revascu
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
PE20070999A1 (es) Emulsion de acido graso esencial intravenosa
ES2523018T3 (es) Ácidos grasos de cadena media aplicables como agentes anti-microbianos
CU20140151A7 (es) Composición farmacéutica útil en la prevención de un evento cardiovascular mayor
AR063773A1 (es) Uso de composiciones nutricionales para prevenir trastornos
ATE538665T1 (de) Lipidzusammensetzung zur verbesserung der hirnfunktion
AR078850A1 (es) Composiciones terapeuticas concentradas de fosfolipidos
CO6220929A2 (es) Composicion complementaria para el tratamiento de enfermedades oculares
ES2648188T3 (es) Composiciones y métodos para la modulación de amidasas específicas para N-aciletanolaminas para ser usadas en la terapia de enfermedades inflamatorias
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
RU2011141102A (ru) Обогащенные омега-3 рыбные парентеральные питательные эмульсии типа масло в воде
BR112014019927A8 (pt) fórmula nutricional, método de preparação da referida fórmula antes da sua ingestão por um indivíduo, uso da referida fórmula, dispositivo para prepará-la e recipiente
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
ES2531516T3 (es) Uso de escina
ES2666322T3 (es) Composiciones farmacéuticas para el tratamiento de trastornos musculares
WO2011097276A8 (en) Methods and compositions for treating arthritis with docosahexaenoic acid
AR105237A1 (es) Método y composiciones nutricionales que contienen fosfatidiletanolamina, esfingomielina y ácido docosahexaenoico
JP2008540484A5 (es)
ES2561207T3 (es) Emulsión grasa para alimentar artificialmente a pacientes gravemente enfermos de cuidados intensivos
RU2009148576A (ru) Экструдаты с улучшенной маскировкой вкуса
RU2012129348A (ru) Композиции, содержащие экстракты andrographics paniculata и gingko biloba в комплексе с фосфолипидами
ES2497667T3 (es) Sistema de emulsificación para usar en cosméticos